PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Congenital adrenal hyperplasia (Hydrocortisone - Congenital adrenal hyperplasia)

Records returned : 13 (on 19 Apr 2025 at 19:30:20). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
06.03.02
12.03.01
Hydrocortisone
Congenital adrenal hyperplasia
Blue
Formulations :
  • Granules in capsules for opening
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
For infants / children on doses BELOW 5mg. Capsules for opening. 0.5mg, 1mg and 2mg only. Doses of 5mg or more - to halve a 10mg tablet and use lower strength capsules to achieve correct dose. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
06.03.02
12.03.01
Congenital adrenal hyperplasia
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
See PAD for guidance on providing reserve supplies for dosing during acute illness
10mg tablets can be halved for doses of 5mg. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
06.03.02
12.03.01
Congenital adrenal hyperplasia
Blue
Formulations :
  • Soluble tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
For patients on dose of 10mg AND unable to swallow solid dose forms. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
06.03.02
12.03.01
Congenital adrenal hyperplasia
Blue
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
2nd line option. Primary Care may initiate prescribing on request from the specialist endocrinology team.
06.03.02
12.03.01
Congenital adrenal hyperplasia
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
For use in infants and children where smaller doses are required.
06.03.02
12.03.01
Congenital adrenal hyperplasia
Non Formulary
Formulations :
  • Buccal tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
(MHRA drug safety update December 2018) https://www.gov.uk/drug-safety-update/hydrocortisone-muco-adhesive-buccal-tablets-should-not-be-used-off-label-for-adrenal-insufficiency-in-children-due-to-serious-risks
01.05.02
06.03.02
11.04.01
12.01.01
Prednisolone
Congenital adrenal hyperplasia
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
- Prednisolone is an alternative treatment for use where multiple daily doses of hydrocortisone are not appropriate. - See PAD for guidance on providing reserve supplies for dosing during acute illness
Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
01.05.02
06.03.02
11.04.01
12.01.01
Congenital adrenal hyperplasia
Blue
Formulations :
  • Soluble tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
- Prednisolone is an alternative treatment for use where multiple daily doses of hydrocortisone are not appropriate. - See PAD for guidance on providing reserve supplies for dosing during acute illness
For patients unable to swallow solid dose forms. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
01.05.02
06.03.02
11.04.01
12.01.01
Congenital adrenal hyperplasia
Blue
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
- Prednisolone is an alternative treatment for use where multiple daily doses of hydrocortisone are not appropriate. - See PAD for guidance on providing reserve supplies for dosing during acute illness
For use in patients who are unable to swallow solid dose forms. Request for primary care prescribing after initiation and stabilisation - at least 1 month supply from specialist team.
06.03.02
Fludrocortisone acetate
Congenital adrenal hyperplasia
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
For advice on dosing of glucocorticoids during acute illness please see PAD page
2nd line option. Requests for primary care prescribing on recommendation from specialist endocrinology team only.
04.06.00
06.03.02
11.04.01
Dexamethasone
Congenital adrenal hyperplasia
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
2nd line option. Requests for primary care prescribing on recommendation from specialist endocrinology team only.
04.06.00
06.03.02
11.04.01
Congenital adrenal hyperplasia
Blue
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
See PAD for guidance on providing reserve supplies for dosing during acute illness
Reserved for patients who are unable to swallow solid dose forms. Requests for primary care prescribing by the specialist endocrinology teams only.
01.05.02
06.03.02
11.04.01
12.01.01
Prednisolone
Congenital adrenal hyperplasia
Non Formulary
Formulations :
  • Enteric coated tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
- Prednisolone is an alternative treatment for use where multiple daily doses of hydrocortisone are not appropriate. - See PAD for guidance on providing reserve supplies for dosing during acute illness
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More